Loading viewer...
investor_presentation
Format: PDF investor_presentation
Breakthroughs that change patients' lives ® November 1, 2022Third Quarter 2022 Earnings Teleconference
Breakthroughs that change patients' lives ®
November 1, 2022Third Quarter 2022
Earnings Teleconference Introduction
Senior Vice President,
Chief Investor Relations Officer 3
Third Quarter 2022 Earnings
Afternoon in NYCNear Term Launches and
High Value Pipeline Programs 4
Third Quarter 2022 EarningsForward -Looking Statements and Non- GAAP Financial Information
Our discussions during this conference call will include forward- looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. We include forward- looking statements about, among other topics, our anticipated operating and financial
performance, reorganizations, business plans, strategy and prospects, our Environmental, Social and Governance (ESG) prioriti es,strategy and goals, expectations for our product
pipeline, in- line products and product candidates, including anticipated regulatory submissions, data read- outs, study starts, approvals, launches, clinical trial results and other
developing data, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, dividends and share
repurchases, plans for and prospects of our acquisitions, dispositions and other business development activities, and our abi lity to successfully capitalize on these opportunities,
manufacturing and product supply, our efforts to respond to COVID -19, including Comirnaty, the Pfizer -BioNTech COVID- 19 Omicron BA.4/BA.5 -adapted bivalent Vaccine (the Pfizer -
BioNTech COVID- 19 bivalent vaccine), other vaccines that may result from the BNT162 program, and our oral COVID -19 treatment (Paxlovid), and our expectations regarding the
impact of COVID -19 on our business, operations and financial results. Among other things, statements regarding revenue and earni ngs per share growth; the development or
commercial potential of our product pipeline, in- line products, product candidates and additional indications, including expected clinical trial protocols, the timing of the initiation and
progress of clinical trials and data read- outs from trials; the timing for the submission of applications for and receipt of reg ulatory approvals; the timing of product launches; expected
profile and labeling; and expected breakthrough, best or first -in-class or blockbuster status of our medicines or vaccines are f orward- looking and are estimates that are subject to
change and clinical trial and regulatory success and availability of supply. These statements are subject to risks, uncertaintie s and other factors that may cause actual results to differ
materially from past results, future plans and projected future results. Additional information regarding these and other fac tors can be found in Pfizer’s Annual Report on Form 10- K for
Preview truncated — download the full document for the complete content.
investor_presentation
129 Pages
investor_presentation
19 Pages
Assertio Holdings (Assertio Therapeutics)